Mountain Province Diamonds Announces Results of Special Meeting of Shareholders, Initiation of 6,000 Metre Discovery-Focused Drill Program
Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
Southern Silver Commences Drilling on the Oro Copper Project, New Mexico; Acquires 100% Interest in the El Sol Claim, CLM Project, Mexico
AbbVie Provides Update Regarding SKYRIZI® for the Treatment of Moderate to Severe Crohn's Disease in the U.S.
Marvel Receives Final TSX Approval, to Move Forward on Highway North Uranium Acquisition - Key Lake - Assumption Agreement
CYPRESS DEVELOPMENT COMMENCES FEASIBILITY STUDY ON CLAYTON VALLEY LITHIUM PROJECT AND ENGAGES WOOD PLC AS INDEPENDENT LEAD AUTHOR
ALR Technologies Announces Successful Preliminary Results for the GluCurve Pet CGM Non-Inferiority Study
Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
AbbVie Seeks New Indication for IMBRUVICA® in Pediatric Patients with Chronic Graft Versus Host Disease
Landmark EPC Adopts ProStar's PointMan Solution to Digitally Map Critical Underground Infrastructure of Boulder, Colorado
Intuit TurboTax Empowers Latino Taxpayers to Do Their Taxes "A Su Manera" Through Integrated Bilingual Efforts
NextSource Materials Announces Preliminary Economic Assessment for a Mine Expansion of 150,000 Tonnes per Annum of SuperFlake Graphite Concentrate
Tinley's Plans First Can Run for Week of March 7, 2022 at Long Beach Facility; Commences Canadian Production at Contract Manufacturers, and Completes Financing
Ivanhoe Mines Announces Exceptional Results of Independent 2022 Feasibility Study for Tier-one Platreef Palladium, Rhodium, Nickel, Platinum, Copper and Gold Project in South Africa
Goldplay Discovers Gold Mineralization at Past Producing Copper Mine in Portugal; Drills 5.87 g/t Au Over 2 m, Near Surface
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
Northern Dynasty: Economic Contribution Assessment Study for Alaska's Pebble Project Shows Project Could Support Thousands of Jobs and Billions of Dollars of Economic Impact Annually While Reducing the Need for the U.S. to Import Copper to Meet its Green Energy Goals
Quixant, the leading global provider of gaming technology announces rebrand and the launch of the Quixant Hub, its enhanced customer support area
Noram Lithium Closes Strategic US$14 Million Financing with Lithium Royalty Corp. and Waratah Capital Advisors Ltd.
Esports Entertainment Group Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
Expanded Ta Khoa Nickel Project Delivers Outstanding Value for Blackstone’s Vertically Integrated Business
Cronos Group Inc. to Hold 2021 Fourth Quarter and Full-Year Earnings Conference Call on March 1, 2022
Lion Copper and Gold Corp. Files Technical Report on SEDAR for Mineral Resource Estimate on the MacArthur Copper Project
Trevali Releases Fourth Quarter and Full Year 2021 Results; Achieves full year Adjusted EBITDA of $102.3 million
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1...
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo plus Yervoy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma...
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy , from Bristol Myers Squibb
KEYTRUDA® Plus LENVIMA® Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ?1%
Fortuna to release fourth quarter and full year 2021 financial results on March 23, 2022; Conference call at 12 p.m. Eastern time on March 24, 2022